Prurigo Nodularis - Dupilumab (Dupixent®)
A Managed Access Protocol (MAP) is in place for medicines for the treatment of moderate-to-severe prurigo nodularis in adults. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of dupilumab (Dupixent®) under the High Tech Arrangement.
Applications for reimbursement approval of dupilumab (Dupixent®) for the treatment of moderate-to-severe prurigo nodularis in adults under the High Tech Arrangement will only be considered from consultant dermatologists with a specialist registration in dermatology, registered with the Irish Medical Council, practising in the healthcare system in the Republic of Ireland, and who have agreed to the terms of the MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the HSE-Managed Access Protocol for dupilumab (Dupixent®) for the treatment of moderate-to-severe prurigo nodularis in adults can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.